Last reviewed · How we verify
Group 2 in Part B and Part C (group-2-in-part-b-and-part-c)
Dose 3 KAN-101 Intravenous (IV) infusion
Due to the provided information, a clinical summary cannot be created. The drug 'group-2-in-part-b-and-part-c' has a discontinued phase and lacks information on its mechanism and indications. Therefore, a factual and concise summary is impossible.
At a glance
| Generic name | group-2-in-part-b-and-part-c |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Dose 3 KAN-101 Intravenous (IV) infusion |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Approved indications
Pipeline indications
- Celiac Disease — discontinued
Common side effects
Key clinical trials
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After (discontinued)
- A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a La (discontinued)
- Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Ar (discontinued)
- Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma (discontinued)
- A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants (discontinued)
- PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients (discontinued)
- A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India (discontinued)
- A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (discontinued)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group 2 in Part B and Part C CI brief — competitive landscape report
- Group 2 in Part B and Part C updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI